Sort
4,870 grants matching “glp 1”
A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy
$1,000,000Nolan Sigal · Tunitas Therapeutics, Inc. · R44 · FY2014 · AI
Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic
$1,000,000Thale Cross Jarvis · Crestone, Inc. · R44 · FY2012 · AI
TP508: A New Drug for Mitigating Lethals Effects of Radiation Exposure
$1,000,000Laurie E Sower · Chrysalis Biotherapeutics, Inc. · R44 · FY2017 · AI
New oral antibiotics focused on treating MDR Gram-negative infections
$1,000,000Charles Testa · Curza Inc · R44 · FY2025 · AI
Advancing a broad-spectrum anti-influenza A virus RNA packaging inhibitor to an IND
$1,000,000Jeffrey S Glenn · Stanford University · R01 · FY2017 · AI
Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic
$1,000,000Thale Cross Jarvis · Crestone, Inc. · R44 · FY2013 · AI
GMP production and GLP safety of bidirectionally targeted SARS-CoV-2 booster vaccine
$1,000,000Ellen Elizabeth Sparger · Tendel Therapies Inc. · R44 · FY2023 · AI
A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis
$1,000,000Gary Fanger · Rise Therapeutics, Llc · R44 · FY2022 · AI
A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy
$1,000,000Nolan Sigal · Tunitas Therapeutics, Inc. · R44 · FY2012 · AI
A Human Fc Bifunctional Fusion Protein to Treat Severe Allergic Asthma
$1,000,000Nolan Sigal · Tunitas Therapeutics, Inc. · R44 · FY2014 · AI
A new class of broad-spectrum antibacterials for treating MDR infections
$1,000,000Charles Testa · Curza Inc · R44 · FY2020 · AI
A new class of broad-spectrum antibacterials for treating MDR infections
$1,000,000Charles Testa · Curza Inc · R44 · FY2021 · AI
Long-acting Growth Hormone for Treating HIV-Associated Adipose Redistribution Syn
$1,000,000George Norbert Cox · Bolder Biotechnology, Inc. · R44 · FY2009 · AI
A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis
$1,000,000Gary Fanger · Rise Therapeutics, Llc · R44 · FY2021 · AI
Long-Acting G-CSF Analog for Treating ARS
$1,000,000George Norbert Cox · Bolder Biotechnology, Inc. · R44 · FY2014 · AI
A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens
$1,000,000Paul Sebahar · Curza Inc · R44 · FY2024 · AI
A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups
$1,000,000Gregory Robert Moe · Omvax, Inc. · R44 · FY2022 · AI
A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens
$1,000,000Paul Sebahar · Curza Inc · R44 · FY2023 · AI
TP508: A New Drug for Mitigating Lethals Effects of Radiation Exposure
$1,000,000Laurie E Sower · Chrysalis Biotherapeutics, Inc. · R44 · FY2016 · AI
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
$1,000,000Gail E Sonenshein · Adecto Pharmaceuticals, Inc. · R44 · FY2019 · CA
Sustained release gel enabling one-stage treatment of prosthetic joint infection
$1,000,000Derek James Overstreet · Sonoran Biosciences, Inc. · R44 · FY2019 · AI
Development of the RXR agonist IRX4204 to treat Multiple Sclerosis and other Immune related Diseases
$1,000,000Rosh Chandraratna · Io Therapeutics, Inc. · R44 · FY2017 · AI
Immunotherapy of MRSA Osteomyelitis
$1,000,000M. Javad Aman · Integrated Biotherapeutics, Inc. · R44 · FY2021 · AI
Optimization of novel pyranopyridine efflux pump inhibitors
$1,000,000Timothy J Opperman · Microbiotix, Inc · R44 · FY2021 · AI
TP508: A New Drug for Mitigating Lethal Effects of Radiatin Exposure
$1,000,000Barbara Maria Olszewska-Pazdrak · Chrysalis Biotherapeutics, Inc. · R44 · FY2012 · AI